# KLK2-comPAS (NCT07164443)

> A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

No report yet. It can be ordered.

- Drugs tested: pasritamig; pasritamig plus JNJ-87189401
- Indication: late-line metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07164443
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Metastatic Castration-resistant Prostatic Neoplasms
- Interventions: Pasritamig; Placebo; Best Supportive Care (BSC); JNJ-87189401
- Enrollment: 1203
- Primary outcome: Overall Survival (OS)

## Indexed commentary on KLK2-comPAS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=klk2-compas-nct07164443